Carboplatin activates the cGAS-STING pathway by upregulating the TREX-1 (three prime repair exonuclease 1) expression in human melanoma

References

• Ma J, Guo W, Li C. Ubiquitination in melanoma pathogenesis and treatment. Cancer Med. 2017;6:1362–1377.
   PubMed Web of Science ®Google Scholar
• Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239–271.
   PubMed Web of Science ®Google Scholar
• Zbytek B, Carlson JA, Granese J, et al. Current concepts of metastasis in melanoma. Expert Rev Dermatol. 2008;3:569–585.
   PubMedGoogle Scholar
• Homet B, Ribas A. New drug targets in metastatic melanoma. J Pathol. 2014;232:134–141.
   PubMed Web of Science ®Google Scholar
• Giavina-Bianchi MH, Pfj G-B, Festa CN. Melanoma: tumor microenvironment and new treatments. An Bras Dermatol. 2017;92:156–166.
   PubMed Web of Science ®Google Scholar
• Freeman TJ, Sayedyahossein S, Johnston D, et al. Inhibition of pannexin 1 reduces the tumorigenic properties of human melanoma cells. Cancers (Basel).2019;11:102.
   Google Scholar
• Ahn J, Xia T, Konno H, et al. Inflammation-driven carcinogenesis is mediated through STING. Nat Commun. 2014;5:5166.
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108–112.
   PubMed Web of Science ®Google Scholar
• Sun L, Wu J, Du F, et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339:786–791.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461:788–792.
   PubMed Web of Science ®Google Scholar
• Martin M, Hiroyasu A, Guzman RM, et al. Analysis of drosophila STING reveals an evolutionarily conserved antimicrobial function. Cell Rep. 2018;23:3537–50.e6.
   PubMed Web of Science ®Google Scholar
• Kwon J, Bakhoum SF. The Cytosolic DNA-Sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26–39.
   PubMed Web of Science ®Google Scholar
• Lee-Kirsch MA, Gong M, Chowdhury D, et al. Mutations in the gene encoding the 3ʹ-5ʹ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007;39:1065–1067.
   PubMed Web of Science ®Google Scholar
• Morita M, Stamp G, Robins P, et al. Gene-targeted mice lacking the Trex1 (DNase III) 3ʹ–>5ʹ DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol. 2004;24:6719–6727.
   PubMed Web of Science ®Google Scholar
• Tomicic MT, Aasland D, Nikolova T, et al. Human three prime exonuclease TREX1 is induced by genotoxic stress and involved in protection of glioma and melanoma cells to anticancer drugs. Biochim Biophys Acta. 2013;1833:1832–1843.
   PubMed Web of Science ®Google Scholar
• Croghan GA, Suman VJ, Maples WJ, et al. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. 2010;116:3463–3468.
   Google Scholar
• Zhao Y, Foster NR, Meyers JP, et al. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non–small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol. 2015;10:172–180.
   Google Scholar
• Castrellon AB, Pidhorecky I, Valero V, et al. The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer. Oncol Rev. 2017;11:324.
   PubMed Web of Science ®Google Scholar
• Yaşayan G, Orun O, Tiber PM, et al. The interactions of human ovarian cancer cells and nanotextured surfaces: cell attachment, viability and apoptosis studies. Cancer. 2019;9:25957–25966.
   Google Scholar
• Souza CM, Gamba Cde O, Campos CB, et al. Carboplatin delays mammary cancer 4T1 growth in mice. Pathol Res Pract. 2013;209:24–29.
   PubMed Web of Science ®Google Scholar
• Fulzele SV, Chatterjee A, Shaik MS, et al. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm Res. 2006;23:2094–2106.
   PubMed Web of Science ®Google Scholar
• Mousavi-Shafaei P, Ziaee -A-A, Zangemeister-Wittke U. Increased cytotoxicity of cisplatin in SK-MEL 28 melanoma cells upon down-regulation of melanoma inhibitor of apoptosis protein. Iran Biomed J.2009;13:27–34.
   Google Scholar
• Na’ara S, Mukherjee A, Billan S, et al. Contemporary multidisciplinary management of sinonasal mucosal melanoma. Onco Targets Ther. 2020;13:2289–2298.
   PubMed Web of Science ®Google Scholar
• Dong X, Jiao L, Li Y, et al. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol. 2009;27(10):1592–1599.
   PubMed Web of Science ®Google Scholar
• Zhu H, Li X, Zhang X, et al. Polymorphisms in mismatch repair genes are associated with risk and microsatellite instability of gastric cancer, and interact with life exposures. Gene. 2016;579:52–57.
   PubMed Web of Science ®Google Scholar
• Prati B, Da Silva Abjaude W, Termini L, et al. Three Prime Repair Exonuclease 1 (TREX1) expression correlates with cervical cancer cells growth in vitro and disease progression in vivo. Sci Rep. 2019;9:351.
   PubMed Web of Science ®Google Scholar
• Gi R, Rodero MP, Crow YJ. Human disease phenotypes associated with mutations in TREX1. J Clin Immunol. 2015;35:235–243.
   PubMed Web of Science ®Google Scholar
• Cai X, Chiu YH, Chen ZJ. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell. 2014;54:289–296.
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Jounai N, Takeshita F, et al. Ligand-induced ordering of the C-terminal tail primes STING for phosphorylation by TBK1. EBioMedicine.2016;9:87–96.
   Google Scholar
• Hemphill WO, Simpson SR, Liu M, et al. TREX1 as a novel immunotherapeutic target. Front Immunol. 2021;12:1016.
   Google Scholar